Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Efficacy of L-cysteine in Prevention of Cluster Headache

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Biohit Oyj
The Finnish Funding Agency for Technology and Innovation (TEKES)
Information provided by (Responsible Party):
Biohit Oyj Identifier:
First received: December 4, 2014
Last updated: January 20, 2016
Last verified: January 2016
The purpose of this study is to validate the novel hypothesis that daily use of L-cysteine (Acetium® capsules) is an effective means to decrease the frequency of (or completely abort) the attacks of cluster headache.

Condition Intervention
Cluster Headache
Drug: Acetium
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy of L-cysteine in Prevention of Cluster Headache. Randomized Intervention Trial With a Medical Device (Acetium® Capsules)

Resource links provided by NLM:

Further study details as provided by Biohit Oyj:

Primary Outcome Measures:
  • The frequency of headache attacks per week [ Time Frame: 1 month ]
    The frequency of headache attacks per week, either during the entire treatment period or during the last treatment interval is compared with the baseline frequencies, to disclose differences between the two study arms.

Estimated Enrollment: 100
Study Start Date: June 2014
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Acetium
Patient will administer Acetium capsules (100mg l-cysteine) twice a day for one month
Drug: Acetium
Capsule for oral administration contains L-cysteine 100mg
Placebo Comparator: Placebo
Patient will administer placebo capsules twice a day for one month
Drug: Placebo
A placebo capsule matching Acetium for oral administration.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18-65 years male/female
  • episodic and chronic cluster headache
  • the subjects should report cluster headache attacks with the frequency from one every second day up to five per day. The individual attacks should last from 15 minutes to 3h.

Exclusion Criteria:

  • patients who meet the International Classification of Headache Disorders II criteria for medication overuse
  • patients who have taken anti-psychotics or anti-depressant medications during the previous 3 months
  • patients who abuse alcohol or other drugs
  • potentially fertile and sexually active women who do not practise contraception
  • other acute or chronic pain disorders
  • severe psychiatric disease
  • infections
  • malignancy
  • short life expectancy
  • cardiovascular disease
  • cerebrovascular disease
  • uncontrolled hypertension
  • degenerative central nervous system diseases
  • pregnant and lactating women
  • regular users of Acetium capsules for other indications
  • renal dysfunction or cystinuria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02310828

Lääkärikeskus Aava, Helsingin Päänsärkykeskus Oy Recruiting
Helsinki, Finland, 00100
Contact: Mikko Kallela, MD, PhD    0035850 5910702   
Contact: Anne Nyrhinen    0035850 5910702   
Principal Investigator: Mikko Kallela, MD, PhD         
Sub-Investigator: Markus Färkkilä, MD, PhD         
Terveystalo, Kamppi Recruiting
Helsinki, Finland, 00100
Contact: Petra Keski-Säntti, MD, PhD    00358503738938   
Principal Investigator: Petra Keski-Säntti, MD,PhD         
Terveystalo, Jyväskylä Recruiting
Jyväskylä, Finland, 40100
Contact: Matti Ilmavirta, MD, PhD    0035850-5631802   
Contact: Anna Kinnunen    0035850-5631802   
Principal Investigator: Matti Ilmavirta, MD, PhD         
Terveystalo, Oulu Recruiting
Oulu, Finland, 90101
Contact: Mikko Kärppä, MD, PhD    0035810 345 2931   
Contact: Jaana Vainionpää    0035810 345 2931   
Principal Investigator: Mikko Kärppä, MD, PhD         
Terveystalo, Tampere Recruiting
Tampere, Finland, 33100
Contact: Marja-Liisa Sumelahti, MD, PhD    040 587 4149   
Contact: Outi Salminen   
Principal Investigator: Marja-Liisa Sumelahti, MD, PhD         
Terveystalo, Turku Recruiting
Turku, Finland, 20100
Contact: Markku Nissilä, MD    00358400 788 020   
Contact: Sanna Hannukainen    00358505220271   
Principal Investigator: Markku Nissilä, MD         
Sub-Investigator: Nina Suvanto-Collán, MD         
Sponsors and Collaborators
Biohit Oyj
The Finnish Funding Agency for Technology and Innovation (TEKES)
Study Chair: Kari Syrjänen, MD, PhD Biohit Oyj
  More Information

Responsible Party: Biohit Oyj Identifier: NCT02310828     History of Changes
Other Study ID Numbers: AC-CLUSTPREV-1
Study First Received: December 4, 2014
Last Updated: January 20, 2016

Keywords provided by Biohit Oyj:
Cluster headache
Migrainous neuralgia
Horton's headache
Histaminic cephalalgia

Additional relevant MeSH terms:
Cluster Headache
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Trigeminal Autonomic Cephalalgias
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases processed this record on May 25, 2017